Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
BURLINGTON, Mass., March 01, 2018 -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer and Troy Ignelzi, chief financial officer of scPharmaceuticals, will present at the Cowen 38th Annual Health Care Conference at 10:40 a.m. ET on Wednesday, March 14, 2018, at the Boston Marriott Copley Plaza in Boston, MA.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.scpharmaceuticals.com for ninety days.
About scPharmaceuticals
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (IV) delivery.
Contacts:
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
[email protected]
Christopher F. Brinzey
Westwicke Partners, 339-970-2843
[email protected]
